Search Results for "CT P6 Celltrion"

19:21 EST 2nd December 2016 | BioPortfolio

Matching Channels


Matching News

Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership

NewsTeva Pharmaceutical Industries Ltd., Celltrion, Inc., and Celltrion Healthcare announce that the companies have entered into an exclusive partnership to commercialize two of Celltrion’s mAb bios...

Teva, Celltrion partner on biosimilar commercialization

David SalazarTeva and Celltrion on Thursday announced a new exclusive partnership centered on commercializing two of Celltrion’s biosimilar candidates in the United States and Canada.  read...

Teva, Celltrion Announce Biosimilar Commercial Partnership

PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Ltd. (TEVA), Celltrion Inc. and Celltrion Healthcare announced that they have entered into an exclusive partnership to commercialize two of C...

Teva and Celltrion to partner on biosimilars

Israeli generics giant Teva Pharmaceutical Industries (Teva) and South Korean biotechnology company Celltrion announced on 7 October 2016 that they had entered into an exclusive partnership for two of...

BRIEF-Teva and Celltrion report exclusive biosimilar commercial partnership

* Teva and Celltrion healthcare will share profit from commercialization of mab biosimilars

Teva partners with Celltrion in $150 million MAb biosimilars deal

Teva Pharmaceutical Industries has entered into an exclusive partnership with South Korea’s Celltrion…

Teva to buy Korea's Celltrion?

Biospectrum Celltrion's acquisition will help Teva boost its biosimilars portfolio [Read more]

Celltrion, Teva in deal for two biosimilars

Celltrion Inc. (KOSDAQ:068270) granted Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) exclusive rights to commercialize two of Celltrion's proposed biosimilars in the U.S. and Canada. The deal includ...

Matching PubMed Articles

Search Whole site using Google

Quick Search
Advertisement Advertisement